All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Glofit-GemOx vs R-GemOx for R/R DLBCL: Results from phase III STARGLO trial
|
Results from the phase III STARGLO trial (NCT04408638) of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL were published in The Lancet by Abramson et al.1 The primary efficacy endpoint was OS. |
| Key learnings |
| With a median follow-up of 11.3 months, OS was longer for Glofit-GemOx vs R-GemOx (HR, 0.59; 95% CI, 0.40–0.89; p = 0.011). |
| At a median follow-up of 20.1 months, the updated analysis showed that median OS (25.5 months vs 12.9 months; p = 0.0064) and median PFS (13.8 months vs 3.6 months; p < 0.0001) were higher for Glofit-GemOx vs R-GemOx. |
| Safety of Glofit-GemOx was consistent with the known safety profiles of the individual agents. AE rates were higher with Glofit-GemOx vs R-GemOx (100% vs 96%). CRS occurred in 44% of patients in the Glofit-GemOx group, and most were low grade (Grade 1, 31%; Grade 2, 10%; and Grade 3, 2%). |
| The efficacy and tolerable safety data from the phase III STRAGLO trial support the use of Glofit-GemOx in the treatment of patients with R/R DLBCL. |
Abbreviations: AE, adverse event; CI, confidence interval; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; Glofit-GemOx, glofitamab plus gemcitabine and oxaliplatin; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; R-GemOx, rituximab plus gemcitabine and oxaliplatin; R/R, relapsed/refractory.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What is your preferred therapy class when planning treatment for a patient with R/R DLBCL after 2 or more lines of systemic therapy ?
